Article – Revolutionising the Genetic Medicine Landscape with Enzymatic DNA
Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets new industry standards for speed, purity, and scalability, overcoming the limitations of traditional plasmid DNA.
In this article, Jill Makin, Chief Scientific Officer at Touchlight, explores how synthetic DNA is revolutionising biomanufacturing across a wide range of genetic medicines, including DNA and mRNA vaccines, non-viral gene therapies, viral vectors for gene and cell therapies, and genome editing technologies.
The dbDNA™ Advantage
- Rapid, linear production scale-up
- High purity with no bacterial sequences
- Complex sequences up to 30kb
- Smaller manufacturing footprint
- FDA DMF and clinical adoption across modalities
As a leading provider of synthetic DNA, Touchlight supplies dbDNA™ to hundreds of biotech and pharmaceutical companies globally. Our robust IP portfolio and best-in-class production facilities ensure unparalleled quality and capacity.
We’re not stopping there. Touchlight is pioneering the future of DNA technology with breakthrough innovations like MegaBulb DNA (m-bDNA) for next-gen CRISPR gene editing. Access the article to learn more.
Author – Jill Makin
Access the article here:
About doggybone DNA (dbDNA™)
Doggybone or dbDNA™ is linear, double stranded, covalently closed DNA vector which is produced in an enzymatic manufacturing process. It can incorporate a gene of interest from 600bp to >20kb making it very flexible to support a range of genetic medicines.